Search research articles
Contact Us
Filters
Showing results (41-50 of 46) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 46 results.
ESMO Open
|
November 8, 2025
Association between adjuvant chemotherapy and outcomes in resected locoregional recurrence of hormone receptor-positive HER2-negative breast cancer: a multi-institutional retrospective study
Y Ozaki, E Tokuda, Y Sagara, et al.
Breast Cancer Research and Treatment
|
March 25, 2017
Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari)
H Kawaguchi, N Masuda, T Nakayama, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 6, 2025
Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis
H S Rugo, E Tokunaga, H Iwata, et al.
ESMO Open
|
August 10, 2023
Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer
G Viale, M Basik, N Niikura, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 14, 2025
Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial
K L Jhaveri, P Neven, M L Casalnuovo, et al.
ESMO Open
|
April 10, 2026
Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial
G Curigliano, J O'Shaughnessy, F-C Bidard, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 46) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 46 results.
ESMO Open
|
November 8, 2025
Association between adjuvant chemotherapy and outcomes in resected locoregional recurrence of hormone receptor-positive HER2-negative breast cancer: a multi-institutional retrospective study
Y Ozaki, E Tokuda, Y Sagara, et al.
Breast Cancer Research and Treatment
|
March 25, 2017
Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari)
H Kawaguchi, N Masuda, T Nakayama, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 6, 2025
Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis
H S Rugo, E Tokunaga, H Iwata, et al.
ESMO Open
|
August 10, 2023
Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer
G Viale, M Basik, N Niikura, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 14, 2025
Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial
K L Jhaveri, P Neven, M L Casalnuovo, et al.
ESMO Open
|
April 10, 2026
Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial
G Curigliano, J O'Shaughnessy, F-C Bidard, et al.
Page
of 5